Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results

Evanthia Galanis, Jan Craig Buckner, Robert P. Dinapoli, Bernd W. Scheithauer, Robert Brian Jenkins, Chiao Hua Wang, Judith R. O'Fallon, Gist Farr

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Object. Gliosarcoma, a rare malignancy of the central nervous system, consists of gliomatous and sarcomatous elements. There are conflicting reports regarding its aggressiveness and cell line of origin compared with those of glioblastoma multiforme (GBM). The goal of this study was to compare clinicopathological features such as disease-free survival time and actual survival time in patients with gliosarcoma with a matched group of patients with GBM as well as with the entire group of patients with GBM. Methods. The authors report on 18 cases of gliosarcoma derived from a series of 748 Grade 4 astrocytoma cases that were part of four consecutive randomized Phase III trials conducted between 1979 and 1996. In this series the gliosarcoma group represented only 2.4% of all GBMs and included 11 men and seven women with a median age of 61.5 years (range 31-81 years). The median tumor size was 5 cm (range 2-8 cm). The locations, all supratentorial, included temporal in 44%, parietal in 28%, frontal in 17%, and occipital in 11%. The 18 patients with gliosarcomas, all Grade 4 (World Health Organization classification), were compared with the entire group of 730 patients with GBM and a control group of 18 patients with GBM matched for known prognostic factors including patient age, randomization date, performance status, extent of resection, and protocol number. Patients in all treatment groups received radiation and nitrosourea-based chemotherapy. The median time to progression and the median survival times for the patients with gliosarcoma were 28.0 and 35.1 weeks as compared with 24.7 and 41.6 weeks for the entire group of patients with GBM (log rank test, p = 0.94 and 0.27, respectively) and 16.7 and 34.4 weeks in the control group (p = 0.20 and 0.84, respectively). In previous molecular cytogenetic analyses of gliosarcoma these authors have shown similar genetic changes in the gliomatous and sarcomatous components. Conclusions. The data obtained in this study support the conclusion that gliosarcoma shares significant clinical and genetic similarities with GBM and that the same principles should be applied for patient enrollment in research protocols and treatment for these two kinds of tumor.

Original languageEnglish (US)
Pages (from-to)425-430
Number of pages6
JournalJournal of Neurosurgery
Volume89
Issue number3
StatePublished - Sep 1998

Fingerprint

Gliosarcoma
Glioblastoma
Neoplasms
Therapeutics
Control Groups
Survival
Cytogenetic Analysis
Astrocytoma
Clinical Protocols
Random Allocation
Disease-Free Survival

Keywords

  • Brain neoplasm
  • Glioblastoma multiforme
  • Gliosarcoma

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Clinical outcome of gliosarcoma compared with glioblastoma multiforme : North Central Cancer Treatment Group results. / Galanis, Evanthia; Buckner, Jan Craig; Dinapoli, Robert P.; Scheithauer, Bernd W.; Jenkins, Robert Brian; Wang, Chiao Hua; O'Fallon, Judith R.; Farr, Gist.

In: Journal of Neurosurgery, Vol. 89, No. 3, 09.1998, p. 425-430.

Research output: Contribution to journalArticle

Galanis, Evanthia ; Buckner, Jan Craig ; Dinapoli, Robert P. ; Scheithauer, Bernd W. ; Jenkins, Robert Brian ; Wang, Chiao Hua ; O'Fallon, Judith R. ; Farr, Gist. / Clinical outcome of gliosarcoma compared with glioblastoma multiforme : North Central Cancer Treatment Group results. In: Journal of Neurosurgery. 1998 ; Vol. 89, No. 3. pp. 425-430.
@article{f3f3a22e6e704b79b6833508f95f3342,
title = "Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results",
abstract = "Object. Gliosarcoma, a rare malignancy of the central nervous system, consists of gliomatous and sarcomatous elements. There are conflicting reports regarding its aggressiveness and cell line of origin compared with those of glioblastoma multiforme (GBM). The goal of this study was to compare clinicopathological features such as disease-free survival time and actual survival time in patients with gliosarcoma with a matched group of patients with GBM as well as with the entire group of patients with GBM. Methods. The authors report on 18 cases of gliosarcoma derived from a series of 748 Grade 4 astrocytoma cases that were part of four consecutive randomized Phase III trials conducted between 1979 and 1996. In this series the gliosarcoma group represented only 2.4{\%} of all GBMs and included 11 men and seven women with a median age of 61.5 years (range 31-81 years). The median tumor size was 5 cm (range 2-8 cm). The locations, all supratentorial, included temporal in 44{\%}, parietal in 28{\%}, frontal in 17{\%}, and occipital in 11{\%}. The 18 patients with gliosarcomas, all Grade 4 (World Health Organization classification), were compared with the entire group of 730 patients with GBM and a control group of 18 patients with GBM matched for known prognostic factors including patient age, randomization date, performance status, extent of resection, and protocol number. Patients in all treatment groups received radiation and nitrosourea-based chemotherapy. The median time to progression and the median survival times for the patients with gliosarcoma were 28.0 and 35.1 weeks as compared with 24.7 and 41.6 weeks for the entire group of patients with GBM (log rank test, p = 0.94 and 0.27, respectively) and 16.7 and 34.4 weeks in the control group (p = 0.20 and 0.84, respectively). In previous molecular cytogenetic analyses of gliosarcoma these authors have shown similar genetic changes in the gliomatous and sarcomatous components. Conclusions. The data obtained in this study support the conclusion that gliosarcoma shares significant clinical and genetic similarities with GBM and that the same principles should be applied for patient enrollment in research protocols and treatment for these two kinds of tumor.",
keywords = "Brain neoplasm, Glioblastoma multiforme, Gliosarcoma",
author = "Evanthia Galanis and Buckner, {Jan Craig} and Dinapoli, {Robert P.} and Scheithauer, {Bernd W.} and Jenkins, {Robert Brian} and Wang, {Chiao Hua} and O'Fallon, {Judith R.} and Gist Farr",
year = "1998",
month = "9",
language = "English (US)",
volume = "89",
pages = "425--430",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "3",

}

TY - JOUR

T1 - Clinical outcome of gliosarcoma compared with glioblastoma multiforme

T2 - North Central Cancer Treatment Group results

AU - Galanis, Evanthia

AU - Buckner, Jan Craig

AU - Dinapoli, Robert P.

AU - Scheithauer, Bernd W.

AU - Jenkins, Robert Brian

AU - Wang, Chiao Hua

AU - O'Fallon, Judith R.

AU - Farr, Gist

PY - 1998/9

Y1 - 1998/9

N2 - Object. Gliosarcoma, a rare malignancy of the central nervous system, consists of gliomatous and sarcomatous elements. There are conflicting reports regarding its aggressiveness and cell line of origin compared with those of glioblastoma multiforme (GBM). The goal of this study was to compare clinicopathological features such as disease-free survival time and actual survival time in patients with gliosarcoma with a matched group of patients with GBM as well as with the entire group of patients with GBM. Methods. The authors report on 18 cases of gliosarcoma derived from a series of 748 Grade 4 astrocytoma cases that were part of four consecutive randomized Phase III trials conducted between 1979 and 1996. In this series the gliosarcoma group represented only 2.4% of all GBMs and included 11 men and seven women with a median age of 61.5 years (range 31-81 years). The median tumor size was 5 cm (range 2-8 cm). The locations, all supratentorial, included temporal in 44%, parietal in 28%, frontal in 17%, and occipital in 11%. The 18 patients with gliosarcomas, all Grade 4 (World Health Organization classification), were compared with the entire group of 730 patients with GBM and a control group of 18 patients with GBM matched for known prognostic factors including patient age, randomization date, performance status, extent of resection, and protocol number. Patients in all treatment groups received radiation and nitrosourea-based chemotherapy. The median time to progression and the median survival times for the patients with gliosarcoma were 28.0 and 35.1 weeks as compared with 24.7 and 41.6 weeks for the entire group of patients with GBM (log rank test, p = 0.94 and 0.27, respectively) and 16.7 and 34.4 weeks in the control group (p = 0.20 and 0.84, respectively). In previous molecular cytogenetic analyses of gliosarcoma these authors have shown similar genetic changes in the gliomatous and sarcomatous components. Conclusions. The data obtained in this study support the conclusion that gliosarcoma shares significant clinical and genetic similarities with GBM and that the same principles should be applied for patient enrollment in research protocols and treatment for these two kinds of tumor.

AB - Object. Gliosarcoma, a rare malignancy of the central nervous system, consists of gliomatous and sarcomatous elements. There are conflicting reports regarding its aggressiveness and cell line of origin compared with those of glioblastoma multiforme (GBM). The goal of this study was to compare clinicopathological features such as disease-free survival time and actual survival time in patients with gliosarcoma with a matched group of patients with GBM as well as with the entire group of patients with GBM. Methods. The authors report on 18 cases of gliosarcoma derived from a series of 748 Grade 4 astrocytoma cases that were part of four consecutive randomized Phase III trials conducted between 1979 and 1996. In this series the gliosarcoma group represented only 2.4% of all GBMs and included 11 men and seven women with a median age of 61.5 years (range 31-81 years). The median tumor size was 5 cm (range 2-8 cm). The locations, all supratentorial, included temporal in 44%, parietal in 28%, frontal in 17%, and occipital in 11%. The 18 patients with gliosarcomas, all Grade 4 (World Health Organization classification), were compared with the entire group of 730 patients with GBM and a control group of 18 patients with GBM matched for known prognostic factors including patient age, randomization date, performance status, extent of resection, and protocol number. Patients in all treatment groups received radiation and nitrosourea-based chemotherapy. The median time to progression and the median survival times for the patients with gliosarcoma were 28.0 and 35.1 weeks as compared with 24.7 and 41.6 weeks for the entire group of patients with GBM (log rank test, p = 0.94 and 0.27, respectively) and 16.7 and 34.4 weeks in the control group (p = 0.20 and 0.84, respectively). In previous molecular cytogenetic analyses of gliosarcoma these authors have shown similar genetic changes in the gliomatous and sarcomatous components. Conclusions. The data obtained in this study support the conclusion that gliosarcoma shares significant clinical and genetic similarities with GBM and that the same principles should be applied for patient enrollment in research protocols and treatment for these two kinds of tumor.

KW - Brain neoplasm

KW - Glioblastoma multiforme

KW - Gliosarcoma

UR - http://www.scopus.com/inward/record.url?scp=0031721858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031721858&partnerID=8YFLogxK

M3 - Article

C2 - 9724117

AN - SCOPUS:0031721858

VL - 89

SP - 425

EP - 430

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 3

ER -